BGLC vs LHX · rev $99.0K vs P/E 34, rev $5.88B
BioNexus Gene Lab Corp Common stock (BGLC) versus L3Harris Technologies Inc (LHX) — a side-by-side from cached financials, not a winner call.
BioNexus Gene Lab Corp Common stock (BGLC) is a specialty chemicals company listed on NASDAQ.
L3Harris Technologies Inc (LHX) is a aerospace & defense company listed on US.
Latest reported BGLC revenue for 2026-06-30 was $99.0K. Net income was -$830.0K. BGLC currently screens at market cap $6.1M.
Latest reported LHX revenue for 2026-07-03 was $5.88B. Net income was $600.0M. Revenue was up 2.4% from 2026-04-03 to 2026-07-03. LHX currently screens at market cap $58.72B and trailing P/E 34.3.
BGLC currently screens at market cap $6.1M. LHX currently screens at market cap $58.72B and trailing P/E 34.3.
Not investment advice. Open the BGLC and LHX stock pages for the full models.
Not investment advice.